Chafic Karam, MD
Associate Professor of Clinical Neurology
Neuromuscular fellowship director, University of Pennsylvania
Neurology CME course director, University of Pennsylvania
Associate Director, Penn Neuromuscular Division
Department: Neurology
Contact information
3400 Spruce St., 3 West Gates
Philadelphia, PA 19104
Philadelphia, PA 19104
Office: 2156153751
Fax: 2153495579
Fax: 2153495579
Publications
Education:
MD
St Joseph University, 2006.
MD
St Joseph University, 2006.
Post-Graduate Training
Intern, Hotel Dieu de France, 2006-2007.
Intern, Mount Sinai Beth Israel, 2007-2008.
Resident in Neurology, Mount Sinai Beth Israel, 2008-2011.
Fellow in Neuromuscular Disorders, Harvard Neurology at Brigham and Women's Hospital and Massachusetts General Hospital., 2011-2012.
Fellow in Peripheral Nerve Disorders, Mayo Clinic, 2012-2013.
Intern, Hotel Dieu de France, 2006-2007.
Intern, Mount Sinai Beth Israel, 2007-2008.
Resident in Neurology, Mount Sinai Beth Israel, 2008-2011.
Fellow in Neuromuscular Disorders, Harvard Neurology at Brigham and Women's Hospital and Massachusetts General Hospital., 2011-2012.
Fellow in Peripheral Nerve Disorders, Mayo Clinic, 2012-2013.
Certifications
American Board of Psychiatry and Neurology, Neurology Certificate No. 56979 , 2011.
American Board of Psychiatry and Neurology Neuromuscular Medicine Certificate No. 557 , 2012.
United Council for Neurologic Subspecialties Clinical Neuromuscular Pathology Certification , 2015.
Permanent linkAmerican Board of Psychiatry and Neurology, Neurology Certificate No. 56979 , 2011.
American Board of Psychiatry and Neurology Neuromuscular Medicine Certificate No. 557 , 2012.
United Council for Neurologic Subspecialties Clinical Neuromuscular Pathology Certification , 2015.
Description of Clinical Expertise
Peripheral neuropathySelected Publications
Morganroth J, Ljungberg L, Goldstein A, Kallish S, Asher SB, Quinn C, Price RS, Karam C. : Adult-Onset Thymidine Kinase Gene (TK2) Deficiency Neurology. August 2023.Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team.: Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 2023; 22: 383–94 May 2023.
Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. : Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial JAMA Neurol. April 2023.
Nicolas Sarmiento Bustamante, Taha Qarni, Felipe Jorge Simoes Jones, Sami Khella1, Brian Drachman, Janice Pieretti, Chafic Karam: Characteristics of a single-center cohort of patients with hereditary amyloidosis. AAN abstract April 2023.
Taha Qarni, Nicolas Sarmiento Bustamante, Felipe Jorge Simoes Jones, Sami Khella, Brian Drachman, Janice Pieretti, Chafic Karam: Treatment characteristics in a cohort of patients with hereditary transthyretin amyloidosis. AAN abstract April 2023.
Chafic Karam, Julian Gillmore, Gengshi Chen, Nia C Jenkins, Michael J Hale, Gemma MJ Taylor, Jersey Chen, Nicholas Viney, Eugene Schneider : A Multi-Method Approach to an Indirect Treatment Comparison of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy AAN abstract April 2023.
Michael Polydefkis; Emre Aldinc; Nienhuis, ; Karam, Chafic ; Senda Ajroud-Driss; 関島良樹 ; Márcia Waddington Cruz ; Jennifer Barnes ; Paul Nioi ; Simina Ticau : NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy. AAN abstract April 2023.
Mamatha Pasnoor,Vera Bril, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said Beydoun, Tuan Vu, Peter Ulrichts, Benjamin Van Hoorick, 10 Caroline T’joen, 10 Kimiaki Utsugisawa, 11 Jan Verschuuren, Renato Mantegazza, James F. Howard Jr, in collaboration with the ADAPT Investigator Study Group: Longterm Safety, Tolerability, and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Concluding Analyses From the ADAPT+ Study AAN abstract April 2023.
Yarlas A, Lovley A, Brown D, Vera-Llonch M, Khella S, Karam C. : The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy. BMC Neurol. Page: 108, Mar 2023.
Kimiaki Utsugisawa,1 James F. Howard, Jr,2 Vera Bril,3,4 Tuan Vu,5 Chafic Karam,6 Stojan Peric,7 Jan L. De Bleecker,8 Hiroyuki Murai,9 Mamatha Pasnoor,10 Francesco Sacca,11 Andreas Meisel,12 Antonio Guglietta,13 Caroline T’joen,13 Renato Mantegazza,14 in collaboration with the ADAPT Investigator Study Group: Efgartigimod Treatment of Anti-Acetylcholine Receptor Antibody Negative Myasthenia Gravis Patients. Japanese Society for Neuroimmunology (JSNI) 2022 October 2022.